<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01575782</url>
  </required_header>
  <id_info>
    <org_study_id>CHLOROQUINE I-III</org_study_id>
    <nct_id>NCT01575782</nct_id>
  </id_info>
  <brief_title>Chloroquine as an Anti-autophagic Radiosensitizing Drug in Stage I-III Small Cell Lung Cancer</brief_title>
  <acronym>Chloroquine</acronym>
  <official_title>Chloroquine as an Anti-autophagic Radiosensitizing Drug in Stage I-III Small Cell Lung Cancer (SCLC) Patients: a Phase I Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht Radiation Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht Radiation Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chloroquine can make tumor cells less resistant to chemo/radiotherapy. In this trial&#xD;
      chloroquine is given during radiotherapy. The dose is increased in cohorts of at least 3&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor accrual&#xD;
  </why_stopped>
  <start_date type="Actual">May 2014</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>3 months after inclusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response of the tumour (regression, progression, stable disease)</measure>
    <time_frame>2 years after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years after inclusion</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Chloroquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chloroquine</intervention_name>
    <description>Daily intake of Chloroquine during radiotherapy</description>
    <arm_group_label>Chloroquine</arm_group_label>
    <other_name>A-CQ 100mg per tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed stage I-III small cell lung cancer,&#xD;
             excluding malignant pleural/pericardial effusion.&#xD;
&#xD;
          -  At least one measurable disease site, defined as lesion of ≥ 1 cm unidimensionally on&#xD;
             CT-scan&#xD;
&#xD;
          -  WHO performance status 0-2&#xD;
&#xD;
          -  Absolute neutrophil count at least 1800/µl and platelets at least 100000/µl and&#xD;
             hemoglobin at least 6.2 mmol/l.&#xD;
&#xD;
          -  Adequate renal function: calculated creatinine clearance at least 60 ml/min&#xD;
&#xD;
          -  Adequate hepatic function: Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for the&#xD;
             institution; ALT, AST, and alkaline phosphatase ≤ 2.5 x ULN for the institution (in&#xD;
             case of liver metastases ≤ 5 x ULN for the institution)&#xD;
&#xD;
          -  No previous platinum chemotherapy or topo-isomerase-inhibitors for SCLC.&#xD;
&#xD;
          -  Lung function: FEV1 at least 30 % and DLCO at least 30 % of the age predicted value&#xD;
&#xD;
          -  No history of prior chest radiotherapy&#xD;
&#xD;
          -  Life expectancy more than 6 months&#xD;
&#xD;
          -  Willing and able to comply with the study prescriptions&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  Not pregnant or breast feeding and willing to take adequate contraceptive measures&#xD;
             during the study&#xD;
&#xD;
          -  Ability to give and having given written informed consent before patient registration&#xD;
&#xD;
          -  No mixed pathology, e.g. non-small cell plus small cell cancer&#xD;
&#xD;
          -  No recent (&lt; 3 months) severe cardiac disease (NYHA class &gt;1) (congestive heart&#xD;
             failure, infarction)&#xD;
&#xD;
          -  No history of cardiac arrythmia (multifocal premature ventricular contractions,&#xD;
             uncontrolled atrial fibrillation, bigeminy, trigeminy, ventricular tachycardia) which&#xD;
             is symptomatic and requiring treatment (CTC AE 3.0), or asymptomatic sustained&#xD;
             ventricular tachycardia. Asymptomatic atrial fibrillation controlled on medication is&#xD;
             allowed.&#xD;
&#xD;
          -  No cardiac conduction disturbances or medication potentially causing them:&#xD;
&#xD;
          -  QTc interval prolongation with other medications that required discontinuation of the&#xD;
             treatment&#xD;
&#xD;
          -  Congenital long QT-syndrome or unexplained sudden death of first degree relative under&#xD;
             40 years of age&#xD;
&#xD;
          -  QT interval &gt; 480 msec (note: when this is the case on screening ECG, the ECG may be&#xD;
             repeated twice. If the average QT-interval of these 3 measurements remains below 480&#xD;
             msec, patient is eligible)&#xD;
&#xD;
          -  Patients on medication potentially prolongating the QT-interval are excluded if the&#xD;
             QT-interval is &gt; 460 msec (Appendix, table 2).&#xD;
&#xD;
          -  Medication that might cause QT-prolongation or Torsades de pointes tachycardia is not&#xD;
             allowed (Appendix, Table 1). Drugs with a risk of prolongating the QT-interval that&#xD;
             cannot be discontinued are allowed, however, under close monitoring by the treating&#xD;
             physician (Appendix, table 2).&#xD;
&#xD;
          -  Complete left bundle branch block&#xD;
&#xD;
          -  No uncontrolled infectious disease&#xD;
&#xD;
          -  No other active malignancy&#xD;
&#xD;
          -  No major surgery (excluding diagnostic procedures like e.g. mediastinoscopy) in&#xD;
             previous 4 weeks&#xD;
&#xD;
          -  No treatment with investigational drugs in 4 weeks prior to or during this study&#xD;
&#xD;
          -  No chronic systemic immune therapy&#xD;
&#xD;
          -  No known G6PD deficiency&#xD;
&#xD;
          -  Patients must not have psoriasis or porphyria.&#xD;
&#xD;
          -  No known hypersensitivity to 4-aminoquinoline compound.&#xD;
&#xD;
          -  Patients must not have retinal or visual field changes from prior 4-aminoquinoline&#xD;
             compound use.&#xD;
&#xD;
          -  No known prior hypersensitivity to cisplatin, etoposide or chloroquine or any of their&#xD;
             components.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - The opposite of the above&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Lambin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastro Clinic, The Netherlands</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MAASTRO clinic</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6229 ET</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>April 3, 2012</study_first_submitted>
  <study_first_submitted_qc>April 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2012</study_first_posted>
  <last_update_submitted>July 13, 2017</last_update_submitted>
  <last_update_submitted_qc>July 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>small cell lung cancer</keyword>
  <keyword>stage I-III</keyword>
  <keyword>chloroquine</keyword>
  <keyword>Phase I</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chloroquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

